Emerging Trends to Drive Oncology Companion Diagnostics Market Growth at 12% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Oncology Companion Diagnostics Market Size Growth Forecast: What to Expect by 2025?
The oncology companion diagnostics market has experienced substantial recent expansion, projected to escalate from a value of $3.35 billion in 2024 to $3.79 billion in the subsequent year, reflecting a compound annual growth rate (CAGR) of 13.2%; this historical upward trend is largely fueled by several factors, including a rise in patient adverse drug reactions, the mounting requirement for thorough genomic assessments, the expanding worldwide prevalence of cancer, the necessity for therapies tailored to specific patient profiles, and a greater number of ongoing clinical investigations.

How Will the Oncology Companion Diagnostics Market Size Evolve and Grow by 2029?
Anticipated in the coming years is a swift expansion for the oncology companion diagnostics industry, projecting a valuation of $5.96 billion by 2029, underpinned by a compound annual growth rate pegged at 12.0%. This projected upswing throughout the forecasting timeframe stems from several key factors: the growing emphasis on tailored medical treatments, a heightened demand for diagnostic assessments, a greater concentration on individualized cancer therapeutics, escalating global healare spending, and the increasing prevalence of cancer alongside greater public understanding of the disease. Significant movements anticipated within this period encompass breakthroughs in diagnostic methodologies, the proliferation of next-generation sequencing techniques, the incorporation of artificial intelligence capabilities, the advancement of liquid biopsy platforms, the fabrication of companion diagnostic tools designed for point-of-care use, and the introduction of novel testing innovations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

What Drivers Are Propelling the Growth of Oncology Companion Diagnostics Market Forward?
Anticipated escalation in cancer instances is set to fuel the expansion of the market for companion diagnostics in oncology moving ahead.Cancer, defined as a set of intricate ailments stemming from the uncontrolled proliferation and dissemination of aberrant cells within the organism, is seeing its incidence climb due to shifts in lifestyle habits, environmental influences, the prevalence of obesity, tobacco consumption, and inherent genetic predispositions.These oncology companion diagnostics services are instrumental in advancing personalized treatment selection within precision medicine frameworks for cancer, profoundly transforming how the disease is managed by boosting therapeutic success rates, lessening undesirable side effects, aiding participant recruitment for clinical studies, and refining the tracking of ongoing treatments.As an illustration, data shared in May 2024 by the National Cancer Institute, a US governmental body, revealed that in 2022, approximately 20 million new diagnoses and 9.7 million fatalities associated with cancer were documented annually, with forecasts suggesting these figures could reach 29.9 million new cases and 15.3 million deaths yearly by the year 2040.Consequently, the increasing burden of cancer directly pushes forward the growth trajectory of the market for oncology companion diagnostics.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15623&type=smp

Which Emerging Trends Are Transforming the Oncology Companion Diagnostics Market in 2025?
Leading corporations within the oncology companion diagnostics sector are dedicating efforts toward creating novel offerings, specifically in vitro diagnostic assays, in order to secure their prominence in the marketplace. These in vitro diagnostic assays, often abbreviated as IVD tests, represent clinical analyses performed on biological specimens extracted from humans, like blood or tissue, executed externally within a regulated area such as a lab facility. To illustrate, in May of 2022, the American biotechnology firm Illumina Inc. introduced an expanded pan-cancer indication for their existing TruSight Oncology (TSO) Comprehensive (EU) in-vitro diagnostic device. This powerful diagnostic tool furnishes a detailed assessment of the tumor's genetic makeup by examining numerous cancer-related genes and biological markers, thus equipping medical practitioners with the necessary data for choosing appropriate targeted treatments for individuals afflicted with solid tumors. The data derived from this examination importantly includes metrics like the tumor mutational burden (TMB) level and the status of microsatellite instability (MSI), significantly enhancing the accuracy and desired outcomes of patient therapeutic plans.

What Are the Key Segments in the Oncology Companion Diagnostics Market?
The oncology companion diagnosticsmarket covered in this report is segmented -

1) By Product: Instrument; Consumables; Software
2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users

Subsegments:
1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15623&type=smp

Who Are the Key Players Shaping the Oncology Companion Diagnostics Market's Competitive Landscape?
Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

What Geographic Markets Are Powering Growth in the Oncology Companion Diagnostics Market?
North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15623

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.